ANSM
Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug
Cladribine capsules could become the first ever oral treatment for gMG
Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition
SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1
Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use
The neurological disorder affects more than 150,000 people in the UK
Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type
The companies entered into a licensing agreement for the candidate in December last year
Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m
The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies
Merck KGaA and Caris enter oncology partnership worth over $1.4bn
The alliance is aimed at accelerating the development of ADCs for cancer patients
Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m
The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins
Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront
Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer
Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m
The candidate is currently in late-stage development for tenosynovial giant cell tumour
New study finds dose of subcutaneous cladribine could predict MS relapse risk
The disease affects approximately 130,000 people in the UK and currently has no cure
Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn
The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate
Merck KGaA’s MS drug put on partial clinical hold by FDA
Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies